SCD1 expression was also predictive of the response of BRAF-mutated melanoma cells to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, which are used in combination therapy for the treatment of BRAF-mutated melanoma patients [87,167,168,169,170]. This evidence concerns the gene BRAF and melanoma.